Corporate ActionJul 17, 2026, 04:47 PM
NanoViricides Enters At-Market Stock Sales Agreement
AI Summary
NanoViricides, Inc. has entered into an At Market Issuance Sales Agreement with D. Boral Capital LLC. This agreement enables the company to offer and sell shares of its common stock from time to time through an "at the market" offering. The Sales Agent will earn a 2.0% commission on the gross proceeds from these sales. A prospectus supplement was filed in connection with this agreement under the company's existing shelf registration statement.
Key Highlights
- NanoViricides, Inc. entered an At Market Issuance Sales Agreement with D. Boral Capital LLC.
- The agreement allows the company to sell common stock in an "at the market" offering.
- Sales can occur on NYSE American or other existing trading markets.
- The Sales Agent will receive a 2.0% commission on aggregate gross proceeds.
- A prospectus supplement was filed under an existing shelf Registration Statement on Form S-3.
Price Impact
More from NNVC